Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Boehringer Ingelheim Animal Health USA Inc | 272 |
| 2 | University of Pennsylvania | 71 |
| 3 | Novartis AG | 64 |
| 4 | Cerus Corp | 56 |
| 5 | Boehringer Ingelheim Vetmedica GmbH | 44 |
| 6 | F Hoffmann La Roche AG | 39 |
| 7 | Immunogen Inc | 36 |
| 8 | Celgene Corp | 33 |
| 9 | aTyr Pharma Inc | 32 |
| 10 | Pangu Biopharma Ltd | 31 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 1,962 |
| 2 | A61P | Therapeutic activity (drug indications) | 1,922 |
| 3 | C07D | Heterocyclic compounds | 938 |
| 4 | Y02A | Climate change adaptation | 801 |
| 5 | C07K | Peptides | 552 |
| 6 | C12N | Microorganisms, enzymes | 455 |
| 7 | A01N | Preservation of bodies; biocides; pest repellents | 413 |
| 8 | G01N | Investigating / analysing materials | 161 |
| 9 | C07C | Acyclic and carbocyclic compounds | 156 |
| 10 | C12Q | Measuring/testing involving enzymes | 118 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Parasites and Host Interactions | 4 |
| 2 | Cancer therapeutics and mechanisms | 1 |
| 3 | Nematode management and characterization studies | 1 |
| 4 | Parasite Biology and Host Interactions | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Robert Bases | Albert Einstein College of Medicine | 11 |
| 2 | A. Halawani | 10 | |
| 3 | Erich Hirschberg | Columbia University | 10 |
| 4 | J. Newsome | Medical Research Council | 9 |
| 5 | Sydney Archer | Sterling Research Group (United States) | 9 |
| 6 | Dennis B. Leeper | Thomas Jefferson University Hospital | 7 |
| 7 | Frances Mendez | Albert Einstein College of Medicine | 6 |
| 8 | J. Pellegrino | 5 | |
| 9 | Andrew Milligan | Thomas Jefferson University Hospital | 4 |
| 10 | D. A. Berberian | Sterling Research Group (United States) | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Lucanthone Is a Novel Inhibitor of Autophagy That Induces Cathepsin D-mediated Apoptosis | 2010 | 152 | Autophagy in Disease and Therapy |
| Hycanthone: A Frameshift Mutagen | 1971 | 148 | Antibiotic Resistance in Bacteria |
| Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. | 2004 | 129 | DNA Repair Mechanisms |
| Graphene nanoribbons as a drug delivery agent for lucanthone mediated therapy of glioblastoma multiforme | 2014 | 113 | Graphene research and applications |
| A New, Active Metabolite of ‘Miracil D’ | 1965 | 106 | Microbial Natural Products and Biosynthesis |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the chemical composition and molecular weight of Miracol?
What are the major patent classification areas associated with Miracol?
Which organizations hold the most patents related to Miracol?
What research topics are associated with Miracol in published literature?
How has patent activity for Miracol changed in recent years?